This is consistent with the previously discussed findings of Itatani et al., who also demonstrated that granulocyte-colony stimulating factor (G-CSF) secretion by CRC cells enhanced TAN recruitment in CRLM as well as in primary CRC tumors, and conferred similar resistance to anti-VEGF therapy [119]. The gene discussed is CSF3; the disease is colorectal carcinoma.